Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07823920

The Clinical Impact of Serratus Anterior VS. Erector Spinae Plane Block on Pain Management of Tube Thoracostomy in Emergency Department Patients.

In the emergency department, tube thoracostomy is a common critical procedure to manage symptomatic pleural issues such as pneumothorax and pleural effusion.[1] This technique employed to remove air or fluid from the pleural cavity, restore negative intrapleural pressure and let the lungs expand again to help normal cardiopulmonary function to be restored again. [2] However, the procedure is often associated with significant pain, with approximately 50% of patients reporting pain levels between 9-10 out of 10 during the intervention, and for pain management emergency physicians have traditionally combined local anesthetics with opioids or anxiolytics. Yet, these methods have notable drawbacks: opioids carry risks of addiction and adverse side effects (e.g., nausea/vomiting, respiratory depression, delirium), while procedural sedation is time-intensive, requires monitoring, and carries risks of complications such as apnea and hypotension.[3] Local anesthetic infiltration for pain management can also fail to effectively and evenly target the intercostal nerves responsible for chest wall sensation.[4] Ultrasound-guided fascial plane blocks (erector spinae plane and serratus plane blocks) have recently been proposed as targeted alternatives for reliable and extended pain control of tube thoracostomy as each block produces a unique distribution of anesthesia. [5] Despite establishing of these techniques for pain control during thoracic surgeries, its application in emergency settings for tube thoracostomy is underexplored enough yet [6], a gap explicitly identified in the recent literature.[4] Therefore, in this study we evaluate the impact of ESP and SAP block for pain management and overall quality of recovery which practically performed by emergency physicians.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged ≥18 to =<60 years presenting to the ED requiring tube thoracostomy.
  • hemodynamically stable (systolic blood pressure ≥90 mmHg).
  • Able to provide informed consent.

Exclusion criteria

  • Tension pneumothorax or hemodynamic instability requiring immediate tube insertion without time for block performance.
  • Known allergy or hypersensitivity to local anesthetics.
  • Infection or cellulitis overlying the intended needle insertion site.
  • Chronic opioid use/dependence, or substance use disorder that would confound pain and opioid-consumption outcomes.
  • Psychiatric illness, cognitive impairment, intoxication, or severe traumatic brain injury (GCS < 13) precluding reliable pain-score reporting or informed consent.
  • Body mass index ≥ 30 kg/m² (sonoanatomic landmarks less reliable).
  • Patients with spinal injury.
  • Patinets with fracture rib.

Treatment and study plan

serratus anterior plane blocks

Procedure

Ultrasound-guided fascial plane block,serratus plane blocks for reliable and extended pain control of tube thoracostomy using 20-30 mL of bupivacaine 0.25%

Erector Spinae Plane Block

Procedure

Ultrasound-guided fascial plane block,Erector spinae plane block for reliable and extended pain control of tube thoracostomy using 20-30 mL of bupivacaine 0.25%.

Primary outcomes

  1. Intraprocedural pain score (NRS 0-10) recorded immediately after tube insertion and pleural fixation.

    Time frame: 24 HR

Secondary outcomes

  1. Total rescue opioid/sedative dose.

    Time frame: 24 HR

  2. Time required to perform the block (needle-in to needle-out).

    Time frame: first 24 HR

  3. procedure-related complications (pneumothorax, hematoma, local anesthetic systemic toxicity, block failure).

    Time frame: first 24 HR

Study contacts

Contact information is provided by the study sponsor or research team.

Arwa Salah Arwa

CONTACT

[email protected]

00201156748809

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Important dates

Study start
2027
Primary completion
2029
Study completion
2029
First posted
Sep 17, 2026
Registry last updated
Sep 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.